Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
- 11 August 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in International Reviews of Immunology
- Vol. 36 (6), 352-359
- https://doi.org/10.1080/08830185.2017.1346092
Abstract
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematological malignancies and autoimmune diseases. The use of RTX is related to the development of hypogammaglobulinemia and infections. Aim of this review is to summarize the evidence supporting the association of specific risk factors with the development of hypogammaglobulinemia and infections post-RTX. Immunological complications are more common in patients with malignant diseases as compared to non-malignant diseases. Moreover, the use of more than one dose of RTX, maintenance regimens, low pre-treatment basal immunoglobulin levels and the association with Mycophenolate and purine analogues represent risk factors for the development of hypogammaglobulinemia. The number of RTX courses, the evidence of low IgG levels for more than 6 months, the use of G-CSF, the occurrence of chronic lung disease, cardiac insufficiency, extra-articular involvement in patients with rheumatoid arthritis, low levels of IgG and older age have been correlated with a higher risk of infections. Even though the heterogeneity of the studies in terms of study population age and underlying disease, RTX schedules as well as differences in pre-treatment or concomitant therapy doesn't allow drawing definitive conclusions, the study of the literature highlight the association of specific risk factors with the occurrence of hypogammaglobulinemia and/or infections. A long term randomized controlled clinical trial could be useful to define a personalized evidence-based risk management plan for patients treated with RTX.Keywords
This publication has 74 references indexed in Scilit:
- Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with RituximabBMC Blood Disorders, 2013
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals Of The Rheumatic Diseases, 2012
- Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing RegimensPublished by The American Association of Immunologists ,2011
- Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal LeukoencephalopathyThe Oncologist, 2010
- Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case seriesBMC Neurology, 2009
- Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantationBritish Journal of Haematology, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Risk factors for infection in haematology patients treated with rituximabEuropean Journal of Haematology, 2008
- A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal TransplantationAmerican Journal of Transplantation, 2008
- Rituximab therapy for steroid-dependent minimal change nephrotic syndromePediatric Nephrology, 2006